Ovid Therapeutics Inc. (OVID)
NASDAQ: OVID · Real-Time Price · USD
2.635
+0.015 (0.57%)
Aug 6, 2026, 11:18 AM EDT - Market open

Ovid Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
7.127.250.570.391.5208.38
Revenue Growth
1199.63%1181.27%44.39%-73.91%-99.28%1551.57%
Gross Profit
7.127.250.570.391.5208.38
Operating Income
-47.74-42.44-61.89-59.28-55.55124.21
Net Income
-12.16-17.41-26.43-52.34-54.17122.83
Earnings Per Share
-0.29-0.23-0.37-0.73-0.771.76
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
155.5269.6453.08105.83129187.8
Total Debt
13.0713.4214.761616.540
Net Cash (Debt)
142.4556.2238.3289.83112.47187.8
Net Cash Growth
398.68%46.70%-57.34%-20.13%-40.11%160.71%
Net Cash Per Share
1.580.760.541.271.602.76

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-41.95-38.33-55.96-45.78-55.23118.61
Capital Expenditures
---0.07-0.04-1.22-0.18
Free Cash Flow
-41.95-38.33-56.03-45.82-56.45118.43
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
-670.25%-585.20%-10933.70%-15122.70%-3696.44%59.61%
Pretax Margin
-170.71%-240.13%-4670.14%-13351.79%-3604.66%59.58%
Profit Margin
-170.71%-240.13%-4670.14%-13351.80%-3604.66%58.95%
FCF Margin
-589.06%-528.60%-9898.76%-11689.00%-3756.55%56.83%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
-----1.82
Forward PE
-4.444.444.444.444.44
P/FCF Ratio
-----1.91
PS Ratio
68.6629.26119.20580.6887.221.08